Gathering Global Insights Toward the Further Refinement of Lung Cancer Screening
Menée en Chine auprès de 30 565 personnes fumeuses ou n'ayant jamais fumé (âge moyen : 57,1 ans ; durée de suivi : 139 011 personnes-années), cette étude examine, en fonction de la consommation tabagique et de la catégorie d'âge, le risque de cancer du poumon après une tomographie numérique à faible dose de rayonnement dont le résultat s'est avéré négatif puis détermine l'intérêt d'étendre le délai entre deux sessions de dépistage
Over the last 2 decades, we have seen substantial advances in the evidence for, and adoption of, lung cancer screening (LCS) with low-dose computed tomography (LDCT). Publication of results from the National Lung Screening Trial in 2011, demonstrating a 20% lung cancer mortality reduction for high-risk current and former smokers receiving LCS with LDCT relative to chest radiography, and a recommendation from the US Preventive Services Task Force in 2014, established LCS with LDCT as a covered benefit in the US. With time, additional clinical trials, including the Dutch-Belgian lung cancer screening trial have demonstrated that the mortality benefits achievable with LDCT LCS are not exclusive to US populations. As LCS gains traction worldwide, we continue to gather valuable insights into how its eligibility criteria and follow-up recommendations can be refined to optimize the mortality benefits of early lung cancer detection.
JAMA Network Open , éditorial en libre accès, 2026